Crinetics (CRNX) Pharmaceuticals announced the first patient has been dosed in the Phase 1/2 study evaluating CRN09682 in patients with metastatic or locally advanced somatostatin receptor type 2-positive neuroendocrine tumors and other SST2-expressing solid tumors. CRN09682 is the lead candidate from Crinetics’ proprietary nonpeptide drug conjugate platform, which leverages the company’s expertise in GPCR drug discovery and small molecule design to develop a pipeline of modular targeted therapies for endocrine and endocrine-related tumors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRNX:
- Crinetics randomizes first patient in CAREFNDR trial
- Buy Rating Justified by Strategic Initiatives and Growth Prospects at Crinetics Pharmaceuticals
- Crinetics price target raised to $45 from $40 at Goldman Sachs
- Crinetics Pharma’s Positive Earnings Call Highlights PALSONIFY Success
- Crinetics Pharmaceuticals: Strong Market Entry and Financial Position Support Buy Rating